The Partnership Provides Expanded Access to the Award Winning MAGPIX® Multiplexing Instrument

AUSTIN, Texas,– Luminex Corporation (NASDAQ: LMNX) today announced that it has extended its global sales and distribution agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) to 2023. In addition, Luminex has granted Bio-Rad global sales and distribution rights for Luminex’s award-winning MAGPIX multiplexing instrument.

As part of the agreement, Bio-Rad will now offer the full range of Luminex’s xMAP® systems including the MAGPIX system, a compact, flexible instrument that simultaneously detects up to 50 different analytes (including proteins and nucleic acids) on a single sample quickly, accurately and reproducibly.

“We are very pleased to extend our sales and distribution agreement and to have Bio-Rad as a global distribution partner for MAGPIX,” said Michael F. Pintek, senior vice president of operations at Luminex. “As a leader in the life science research market, Bio-Rad can provide researchers additional access for this highly innovative instrument that offers a broad range of applications. Together we can accelerate the pace of research and advance healthcare for people around the world.”

“We are looking forward to offering MAGPIX to our customers as part of a complete product offering featuring our analysis software and extensive assay menu,” said Brad Crutchfield, Bio-Rad vice president and group manager Life Science Group. “This partnership with Luminex reflects Bio Rad’s ongoing commitment to providing the global research community with innovative technologies that will lead to scientific discovery and improved healthcare.”

About MAGPIX

Providing nearly 5,000 data points in under an hour, MAGPIX was designed to meet the needs of laboratories, academic researchers and scientists who, until now, have not been able to take advantage of the power of multiplexing because of resource and space limitations.

MAGPIX saves vital time in the laboratory, produces faster, accurate, reproducible results and requires less sample input than existing legacy technologies such as ELISA and Western blot. Based on Luminex’s xMAP® Technology, the easy-to-use MAGPIX instrument is compact – comparable in size to a desktop computer – making it an attractive option to a broad array of laboratories and institutions. MAGPIX was awarded a prestigious 2011 Medical Design Excellence Award for Innovative Design and Contribution and recently received CE IVD mark in Europe.

In the United States, MAGPIX is for research use only. Not for use in diagnostic procedures.

< | >